China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China SHENZHEN, CHINA, June 12, 2023 (GLOBE NEWSWIRE) -- CMS is pleased to announce the NDA of the first Diazepam Nasal Spray has been approved for marketing in China. The Product can meet current...

China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China SHENZHEN, CHINA, May 30, 2023 (GLOBE NEWSWIRE) -- CMS is pleased to announce the NDA of Tildrakizumab Injection under the brand name of ILUMETRI, a monoclonal antibody specifically targeting the p19...

NOTICE TO DISREGARD -- China Medical System Holdings Ltd. SHENZHEN, CHINA, Dec. 21, 2022 (GLOBE NEWSWIRE) -- We are advised by China Medical System Holdings Ltd. that journalists and other readers should disregard the news release, "CMS (867.HK) Joins Hand...

China Medical System (867.HK) S&P Global CSA Score Achieved Significant Improvement, Leading the Industry Globally SHENZHEN, CHINA, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Recently, the S&P Global Corporate Sustainability Assessment (S&P Global CSA) released the 2022 Environmental, Social and Governance (ESG)...

CMS Releases Its 2022 Interim Report, Achieves Sustained Growth with Its Platform Strategy SHENZHEN, CHINA, Aug. 26, 2022 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited ("CMS", 867.HK) released its 2022 interim report on August 22. In the first half of 2022, CMS delivered an...